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Introduction. Helicobacter pylori eradication therapy has the potential burden of antibiotic-associated gastrointestinal (GI) side
eﬀects. The occurrence of side eﬀects is among the major drawbacks of such regimens. GI manifestations may be related to
alterations in the intestinal microﬂora. Probiotics can prevent or reduce antibiotic-associated side eﬀects and have an inhibitory
eﬀect on H. pylori. Methods. To deﬁne the eﬃcacy of Lactobacillus reuteri supplementation in H. pylori eradication and in
preventing GI-associated side eﬀects during a second-line levoﬂoxacin triple therapy. 90 H. pylori-positive patients receive for
7 days a second-line triple therapy with esomeprazole, levoﬂoxacin, and amoxicillin with L. reuteri f o r1 4d a y s( g r o u p1 )a n d
without probiotic supplementation (group 2). Each subject received a validated questionnaire to record symptoms everyday for 4
weeks from the start of therapy. H. pylori status and side eﬀects were assessed 6 weeks after treatment. Results. The eradication rate
was signiﬁcantly inﬂuenced by probiotic supplementation with L. reuteri (group 1: 36/45, 80%; group 2: 28/45 62%; P<0.05).
The incidence of nausea and diarrhoea in group 1 was signiﬁcantly lower than that in group 2. Conclusion.I nH. pylori-positive
subjects L. reuteri supplementation increases the eradication rate while reducing the incidence of the most common side eﬀects
associated with antibiotic therapy in second-line treatment.
1.Introduction
Helicobacter pylori (H. pylori), a microaerophilic, gram
negative bacterium that colonises the mucous layer of the
gastric epithelium, is the causative agent of type B gastritis,
peptic ulcer, gastric cancer [1–3], and extradigestive diseases
[4]. At least one-third of the world’s population is infected
with H. pylori. The standard treatment recommended for
H. pylori eradication is a combination of proton-pump
inhibitor (PPI) or ranitidine bismuth citrate, clarithromycin,
and either amoxicillin or nitroimidazole. These regimens
have been able to achieve eradication rates ranging from
65% to 90%; however they have the disadvantage of being
expensiveandcausesideeﬀectswhichrequirethewithdrawal
of therapy and antibiotic resistance can be developed [5].
According to Maastricht III consensus the second-line
treatment should be bismuth-based quadruple therapy (if
available), PPI plus amoxicillin, tetracycline or metronida-
zole[6].Ourgroupreportin2009alevoﬂoxacin-basedtriple
therapy as a valid alternative [7].
2 papers have shown also the superiority of levoﬂoxacin
triple over bismuth quadruple therapy [8, 9].
As regards antibiotic resistance rate a high resistance
versusmetronidazoleandclarithromycinwasreportedinour
country.
An interesting paper by Romano et al. report a high
eradication rate with levoﬂoxacin versus clarithromycin and
thesuccessdependsatleastinpartontheverylowprevalence
in levoﬂoxacin-resistant H. pylori strains in our population
(3%) [10].
Antibiotic-associated gastrointestinal side eﬀects such as
diarrhoea, nausea, vomiting, bloating, and abdominal pain
can represent a serious drawback to anti-H. pylori therapies.
These manifestations have been related to quantitative and2 Gastroenterology Research and Practice
qualitative changes in the intestinal microﬂora because of
unabsorbed or secreted antibiotics in the intestinal content,
with a resulting reduction in normal saprophytic ﬂora, over-
growth and persistence of potentially pathogenic antibiotic-
resistant indigenous strains [11].
At present, treatment failure is a signiﬁcant problem
in clinical practice, and the possibility to use simpler
eradication schemes or new drugs should be regarded as the
most promising way to improve the eﬃcacy of eradication
therapy. Some papers showed that the use of probiotics
during the ﬁrst-line H. pylori therapy improved the patients
compliance and reduced gastrointestinal symptoms [12–14].
A probiotic is deﬁned as a living microbial species that,
on administration, can have a positive eﬀect on bowel
microecology with improved health conditions. At present,
the most studied probiotics are lactic acid-producing bac-
teria, particularly Lactobacillus [15, 16]. Probiotics have
been proven to be useful in the treatment of several
gastrointestinal diseases such as acute infectious diarrhoea
or pouchitis [17, 18]. Moreover, as shown in several studies,
probiotics also show a direct antimicrobial eﬀect [19]. In
particular, probiotics may compete directly with H. pylori,
possibly through the inhibition of adherence, as well as by
producing metabolites and antimicrobial molecules [20].
On this basis, the Maastricht 2–2000 Consensus Report
speculated on the role of probiotic supplementation in the
treatment of H. pylori infection [21].
The implementation of standard anti-H. pylori regimens
with probiotics could be advisable, as they are able to
improve the patient’s compliance by reducing antibiotic-
associated adverse events, thus increasing the number
of patients completing eradication therapy, resulting in
improved eradication rate [22–24]. However, the number
of patients enrolled in these trials was too small to achieve
statistically conclusive results.
Lactobacillus reuteri (L. reuteri) in one of the most
interesting lactobacillus, with some stimulating properties;
in particular, it is antibiotic resistant, improves the immune
response in the gastrointestinal tract, has a therapeutic eﬀect
in acute diarrhoea, reduces the incidence of antibiotic-
associated side eﬀects, and inhibits H. pylori in vitro and
in vivo [25–28]. A recent study reports that a ﬁrst-line
therapy with4-weekL.reuterisupplementation is eﬀectivein
reducing H. pylori bacterial load in humans and theoretically
may help to control gastric inﬂammation [29].
T h ea i mo fo u rs t u d yw a st od e ﬁ n et h ee ﬃcacy of L.
reuteri supplementation in H. pylori eradication and in pre-
venting associated gastrointestinal side eﬀects during anti-H.
pylori infection second-line levoﬂoxacin triple therapy.
2. Methods
2.1. Patients. The study was a single-centre, prospective,
randomised, controlled study performed at the Gastroen-
terology and Internal Medicine Departments of Gemelli
Hospital of Rome, Italy.
All patients are Caucasian and came from the same geo-
graphic area.
Ninety consecutive H. pylori-positive patients were
enrolled from November 2007 to June 2008. Patients were
considered eligible to enter the study if they were between
18 and 65 years old, aﬀected by gastric H. pylori infection as
conﬁrmed by a 13C-urea breath test, submitted to a previous
unsuccessful anti-H. pylori antibiotic treatment. Exclusion
criteria were recent (within the previous 3 months) use
of antimicrobial agents, bismuth compounds, PPI and H2
receptor antagonists, laxatives, antidiarrheal, other probiotic
preparations, alcohol, or drug abuse. Patients with major
concomitant diseases including psychiatric disorders and
pregnant or lactating women were also excluded from the
study. All patients signed a written informed consent. The
study was approved by our Ethical Committee.
2.2. Treatment. Using a permuted block randomization
(1:1), 90 patients were assigned to one of the following
parallel groups.
(i) 45 patients (32 males/13 females, mean age 41.5 ±
11.7) were randomly assigned to receive a triple ther-
apy based on esomeprazole 20mg bid, levoﬂoxacin
500mg bid, and amoxicillin 1gr bid for 7 days plus L.
reuteri (1 × 108, CFU) (Reuﬂor Italchimici Pomezia,
Italy)t.i.dfor14days,duringeradicationtherapyand
1 week thereafter.
(ii) 45 patients (28 males/17 females, mean age 43.1 ±
13.3) were randomly assigned to receive the same
triple therapy without probiotics.
2.3. Side Eﬀects. Each patient was required to complete a
validated daily diary for 2 weeks, starting from the ﬁrst day
of eradication treatment. The diary contains a questionnaire
(slightly modiﬁed from De Boer et al.)[30] evaluating the
onset,intensity,andfrequencyofgastrointestinalsideeﬀects:
taste disturbance, epigastric pain, constipation, skin rash,
nausea, vomiting, abdominal pain, bloating, loss of appetite,
and diarrhoea. Symptom intensity was rated using a scale,
where 0, 1, 2, and 3 corresponded to absent, mild, moderate
and severe symptoms, respectively. An overall judgment
of tolerability was assessed by the patient at the end of
both the ﬁrst and second weeks of treatment. Treatment
compliance was evaluated by counting the vials returned by
the subject (patients who returned <80% of empty vials were
not included in the per protocol population (PP) analysis).
Patients were adequately informed and motivated to therapy,
and strictly.
2.4. Eradication of Helicobacter pylori. H. pylori status was
controlled with the 13C urea breath test performed with
citric acid and 75mg of 13C urea, with the eradication
control test being performed not before 6 weeks after the end
of therapy [31, 32]. A delta value higher than 3.5 units was
considered the cut-oﬀ for positivity.
2.5. Statistical Analysis. To evaluate H. pylori eradication
three variables, previously dichotomised, were analysed: L.
reuteri supplementation (Y versus N), sex (males versusGastroenterology Research and Practice 3
Table 1: HP-eradication: univariate analysis.
Independent variables Subgroups analysed HP eradication rate P value
L. reuteri
supplementation
Y 36 (80%) 0.038
N 27 (60%)
Age <42 y 33 (73.3%) 0.782
≥42 y 30 (66.7%)
Sex Male 40 (88.9%) 0.329
Female 23 (51.1%)
Table 2: HP-eradication: multivariate analysis.
Independent variables P value Odds ratio 95% Conﬁdence
interval
L. reuteri
supplementation 0.026 3.055 1.146–8.150
Age 0.434 1.471 0.559–3.869
Sex 0.195 0.497 0.172–1.430
females), and age (age < median age versus age ≥ median
age). A univariate analysis was performed with the chi-
squared test. The signiﬁcant cut-oﬀ was set at P<0.05.
Signiﬁcant parameters with a P value less than 0.25 at
univariate analysis were entered in a multivariate logistic
regression model to identify independent predictors of H.
pylori eradication. Odds ratio (OR) to achieve H. pylori erad-
ication with 95% conﬁdence intervals (CI) was calculated.
The statistical analysis of side eﬀects was performed
with the chi-square univariate analysis. All variables were
dichotomised into two group: symptoms Y versus symptoms
N and moderate-severe symptoms versus negligible or not
referred symptoms. The signiﬁcant cut-oﬀ was P<0.05.
All analyses were performed using SYSTAT 12.0 for
Windows.
2.6. End Point. The primary end point of the study was to
comparetheeradication rateachieved withthetriple therapy
with or without L. reuteri supplementation.
The secondary end point were the patients compliance
and the occurrence of side eﬀects in the two groups of
diﬀerent treatment.
3. Results
All patients completed the study.
Forty-ﬁve patients were treated with L. reuteri supple-
mentation (group 1) and 45 patients were treated without
probiotic supplementation (group 2).
The per protocol and “intention to treat” analyses were
shown to be the same in our study, because of the absence
of drop out events. The overall patients compliance to both
eradication schemes was good, with all patients completing
the prescribed therapy.
A signiﬁcantly higher eradication rate was achieved in
group1with80%eradicationrate(36/45),comparedto60%
(27/45) in group 2 (P: 0.038). Age (P: 0.782) and sex (P:
0.329) had no signiﬁcant impact on H. pylori eradication
rate (Table 1). L. reuteri, age and sex were evaluated in a
multivariate model of statistical analysis and we found that
L. reuteri supplementation was the only predicting factor in
H. pylori eradication (P: 0.026; odds ratio: 3.055; conﬁdence
interval: 1.146–8.150) (Table 2).
As regards the analysed side eﬀects, taste distortion was
referred by 6 patients (13.3%) of group 1 and by 8 patients
(17.8%) of group 2 (P: 0.561); epigastric pain was reported
by 5 patients (11.1%) of group 1 and 4 patients (8.9%) of
group 2 (P: 0.725); constipation was reported by 8 patients
(17.8%) of group 1 and 11 patients (24.4%) of group 2 (P:
0.438); skin rash was observed in 4 patients (8.9%) of both
groups (P: 1.000). No patients referred moderate or severe
taste disturbance, epigastric pain, constipation and skin rash
of both groups.
Thirty patients (66.7%) of group 1 reported nausea,
19 (42.2%) of them of moderate-severe intensity, while all
patients (100%) of group 2 referred moderate-severe nausea
(P<0.001 both in absolute terms and for moderate-
severe symptoms). No signiﬁcant diﬀerence was reported for
vomiting that was referred by 17 patients (37.8%) of group
1 and 15 patients (33.3%) of group 2 (P: 0.660), with a
moderate severe score by 3 patients (6.7%) of both groups
(P: 1.000). Twenty-nine patients (64.4%) of group 1 and
31 patients (68.9%) of group 2 referred abdominal pain (P:
0.655); this symptom was reported as moderate severe by
6 patients (13.3%) of group 1 and by 12 patients (26.7%)
of group 2 (P: 0.114). Bloating was reported by 35 patients
(77.8%) of group 1 and 37 patients (82.2%) of group 2
(P: 0.598), which was of moderate-severe intensity by 12
patients (26.7%) of group 1 and 8 patients (17.8%) of group
2, respectively (P: 0.310). 36 patients (80%) of group 1 and
33 patients (73.3%) of group 2 referred loss of appetite (P:
0.455), which was of moderate-severe intensity in 11 patients
(24.4%) and 15 patients (33.3%), respectively, (P: 0.352).4 Gastroenterology Research and Practice
Table 3: HP-eradication: univariate analysis of symptom regression.
Symptoms L. reuteri group No L. reuteri group P value
Nausea 32 (66.7%) 45 (100%) <0.001
Moderate-severe nausea 19 (42.2%) 45 (100%) <0.001
Abdominal pain 29 (64.4%) 31 (68.9%) 0.655
Moderate-severe abdominal pain 6 (13.3%) 12 (26.7%) 0.114
Diarrhoea 10 (22.2%) 26 (57.7%) <0.004
Moderate-severe diarrhoea 4 (10%) 15 (57.6%) <0.001
Bloating 35 (77.7%) 37 (82.2%) 0.598
Moderate-severe bloating 12 (26.7%) 8 (17.8%) 0.310
Loss of appetite 36 (80%) 33 (73.3%) 0.455
Moderate-severe loss of appetite 11 (24.4%) 15 (33.3%) 0.352
Vomiting 17 (37.8%) 15 (33.3%) 0.660
Moderate-severe vomiting 3 (6.7%) 3 (6.7%) 1.000
Epigastric pain 5 (11.1%) 4 (8.9%) 0.725
Taste disturbance 6 (13.3%) 8 (17.8%) 0.561
Skin rash 4 (8.9%) 4 (8.9%) 1.000
Constipation 8 (17.8%) 11 (24.4%) 0.438
Diarrhoea was reported by 10 (22.2%) patients of group 1
and 26 (57.7%) of group 2 (P: 0.004); it was moderate-severe
in4 patients(40.0%) and in 15patients (57.6%),respectively
(P: 0.001) (Table 3).
4. Discussion
In the present randomised controlled study we have shown
that patients treated with L. reuteri during a levoﬂoxacin-
based second-line H. pylori therapy experienced a lower
incidence of nausea and diarrhoea compared to subjects
without probiotic supplementation and with a higher eradi-
cation rate. Probiotics may act in a diﬀerent way: by direct
competition with H. pylori or by improving the patients
compliance to therapy reducing the incidence of antibiotic-
associated side eﬀects [33–35]. The direct eﬀect against H.
pylori is supported only by animal and in vitro studies
whileseveralothershaveconﬁrmedthatprobioticsindirectly
improve eradication rate with reduced incidence of side
eﬀects and improved patients compliance [36–38].
Currently, the best studied probiotics are the lactic acid
bacteria, in particular Lactobacillus and Biﬁdobacterium [39–
43].InourstudywehaveusedL.reuteriATCC55730because
previous clinical trials have shown that its administration is
safe in both adults and children, reducing the incidence and
severity of gastrointestinal side eﬀects; moreover it is bile and
acid resistant, adheres to the mucosa and to enterocytes and
inhibits H. pylori growth in vitro and vivo [44, 45].
Previous studies reported that L. reuteri has the cell
surface protein that inhibits in vitro the binding of H. pylori
to receptor glycolipids (asialo-GM1 and sulfatide) [19]. To
conﬁrmthisdataCanduccietal.[26]haverecentlypublished
a randomised placebo-controlled study and have shown an
inhibitory eﬀect of L. reuteri on H. pylori growth with a
signiﬁcant decrease in both 13C-UBT and H. pylori.T h u s ,
L. reuteri seems to exert a beneﬁcial eﬀect during H. pylori
infection resulting in a reduction of bacterial load and
gastric inﬂammation. In the literature, many clinical trials
are reported on the use of single or multiple probiotic strains
administered for H. pylori treatment. Unfortunately, it is
hard to compare these trials because of diﬀerent randomi-
sation, probiotic administration, doses, and concomitant
therapy.
The second aim of our study was to assess whether L.
reuteri could be of help in ameliorating symptoms during H.
pylori triple therapy. We have shown that patients receiving
the probiotic experienced a signiﬁcant improvement of
some gastrointestinal symptoms compared to those without
probiotic supplementation.
In particular symptoms with a lower incidence in group
1t r e a t e dw i t hL. reuteri were diarrhoea and nausea. Previous
studies have shown that oral probiotic treatments during
ﬁrst-line anti-H. pylori regimens were able to reduce the
incidence of diarrhoea, nausea and taste disturbance. It is
well known that antibiotic-associated side eﬀects are com-
mon and are usually the ﬁrst cause of therapy withdrawal. In
fact, antibacterial drugs, can alter the equilibrium between
bacterial concentration and colonic mucosal cells, causing a
prevalence of pathogens over the normal microﬂora. Pro-
biotic supplementation may partially restore the intestinal
physiological microecology [46–48].
A Cochrane analysis showed that antibiotics alter the
microbialbalancewithinthegastrointestinaltractandprobi-
otics [49]. In particular, Lactobacillus spp. and Saccharomyces
boulardii can prevent antibiotic-associated diarrhoea by
restoring the gut microﬂora [42–51].
A recently published paper has shown that L. reuteri is
eﬀective in reducing gastrointestinal symptoms during H.
pylori eradication therapy in children [29–33].
A meta-analysis on the eﬀects of probiotic supplementa-
tion on eradication rates and adverse events during H. pyloriGastroenterology Research and Practice 5
eradication therapy suggests that probiotics are eﬀective in
increasing the eradication rate and can be considered helpful
for patients with eradication failure [52]. However, there
are only two trials which conﬁrm this conclusion: this is
the reason why to conﬁrm this result; we have designed a
randomised controlled trial in a large population.
A major drawback of our study is the lack of a double-
blind controlled design; so the diﬀerence in side eﬀects needs
to be judged with caution.
Our study is the ﬁrst that has evaluated the admin-
istration of L. reuteri in levoﬂoxacin second-line therapy.
It is well known that a second-line therapy results in
success rates from less than 60% to 90% with the most
relevant determinant of success being microbial sensitivity
and patients compliance.
In summary, we conﬁrm that L. reuteri supplementation
during a second-line H. pylori therapy is recommended ﬁrst
of all for a better eradication rate and second for reduced
gastrointestinal side eﬀects. Although this pilot study opens
newareasofinvestigation,furtherstudiesonalargernumber
of patients are required to deﬁne its real clinical application.
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